A Study to Compare the Effectiveness of Tofacitinib Ointment and a Control Cream Along with Light Therapy in Vitiligo

Effectiveness of topical tofacitinib 2 percent ointment versus placebo with whole- body phototherapy in patients with non-segmental vitiligo: A split-body study - Nil

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/01/100845

Enrollment

Registered

2026-01-12

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L80- Vitiligo

Interventions

Intervention1: Nil: Nil Intervention2: 2% tofacitinib ointment plus whole-body NB-UVB phototherapy: In this intra-individual, non-randomized, split-body study, the right side of the body will receive

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients of non-segmental vitiligo involving 5% or more body surface area with distinct lesions over bilateral upper limbs or lower limbs or both sides of the trunk, not crossing midline. irrespective of disease activity. 2) Size of the target patch equal to or more than 5x5 cm.

Exclusion criteria

Exclusion criteria: 1) Patients with segmental Vitiligo. 2) History of previous phototherapy or other immunosuppressive treatment (for patients receiving phototherapy, any systemic or local immunosuppressive therapy, a washout period of 4 weeks is required for systemic treatments and 2 weeks for topical treatments). 3) Patients without distinct lesions over bilateral upper limbs or lower limbs or both sides of the trunk (left and right). 4) Patients of vitiligo with <5% body surface area involvement, who are not candidates for full body NB-UVB phototherapy. 5) Contraindications to the use of NB-UVB. 6) Intake of phototoxic drugs. 7) History of skin malignancy or any current pre-malignant condition. 8) Claustrophobia

Design outcomes

Primary

Measure	Time frame
Proportion of patches achieving F-VASI 75 response at 24 weeks in both groups.Timepoint: At the end of the follow-up at 24 weeks.	—

Secondary

Measure	Time frame
Proportion of patches achieving F-VASI 50 response at 24 weeks in both groups.Timepoint: At the end of the follow-up at 24 weeks.;Proportion of patches achieving vitiligo noticeability scale (VNS) 4 or 5.Timepoint: At the end of the follow-up at 24 weeks.;To compare the mean time taken to achieve F-VASI 50 in both groups.Timepoint:	—

Countries

India

Contacts

Public ContactShubham Guleri

Post Graduate Institute of Medical Education and Research, Chandigarh

drsen_2000@yahoo.com8872004023

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026